Progression risk approach of chronic kidney disease. Experience in Botswana

Authors

  • Rafael Enrique Cruz Abascal Hospital Clínico Quirúrgico Universitario “Arnaldo Milián Castro”, Villa Clara
  • Rafael Luis Pino Pichs Policlínico Comunitario “Aracelio Rodríguez Castellón”, Cumanayagua

Keywords:

disease progression, chronic kidney disease, vascular hypertensive nephropathy, AIDS-associated nephropathy, diabetic nephropathies

Abstract

Introduction: Chronic kidney disease is a major health problem worldwide. Objective: to characterize the progression of this disease in the Princess Marina Hospital of Gaborone, Botswana. Methods: between April 2014 and February 2016, an observational, longitudinal and prospective study was carried out that included 61 adult patients of both sexes in stages 2 to 4 of chronic kidney disease. The age, sex and etiology of the originary nephropathy, comorbidity and laboratory determinations were related. Results: male sex prevailed (37, 60.6%) and the mean age was 61.7 years. Type 2 diabetes mellitus was the most common comorbidity. Thirteen patients (21.31%) showed progression of the disease, while the laboratory determinations and the estimated glomerular filtration rate, in those who did not progress, showed a tendency to improvement, with the exception of cholesterol, which increased discreetly: 4, 78 and 4.94mmol/l (t=1,364, pα=0.371). Conclusions: this study shows that with the adequate follow-up of patients with stage 2 to 4 chronic kidney disease, it is possible to influence their rate of progression.

Downloads

Download data is not yet available.

Author Biographies

Rafael Enrique Cruz Abascal, Hospital Clínico Quirúrgico Universitario “Arnaldo Milián Castro”, Villa Clara

Especialista de II Grado en Nefrología. Máster en Enfermedades infecciosas. Profesor Auxiliar e Investigador Auxiliar de la Universidad de Ciencias Médicas de Villa Clara.

Rafael Luis Pino Pichs, Policlínico Comunitario “Aracelio Rodríguez Castellón”, Cumanayagua

Especialista de I Grado en Medicina Interna. Profesor Instructor.

References

1. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, et al. Excerpts from the United States Renal Data System´s 2000 annual data report: atlas of end stage renal disease in the United States. Am J Kidney Dis [Internet]. 2005 Ene [citado 20 Nov 2017];45 (1 suppl 1): A5-7, S1-280. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/15640975

2. Yuste C, Barraca D, Aragoncillo-Sauco I, Vega-Martínez A, Abad S, Verdalles-Guzmán U, et al. Factors related with the progression of chronic kidney disease. Nefrologia [Internet]. 2013 [citado 20 Nov 2017]; 33(5):685-91. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24089160

3. Virú-Loza MA, Palacios-Guillén AM. Hiperuricemia y progresión del compromiso cardiorrenal crónico. Revista Peruana de Medicina Experimental y Salud Pública [Internet]. 2014 [citado 20 Nov 2017];31(3):530-4. Disponible en: http://www.rpmesp.ins.gob.pe/index.php/rpmesp/article/view/92/1931

4. Santamaría Olmoa R, Gorostidi Pérez M. Presión arterial y progresión de la enfermedad renal crónica. NefroPlus [Internet]. 2013 [citado 20 Nov 2017];5(1):4-11. Disponible en: http://www.elsevier.es/es-revista-nefroplus-485-articulo-presion-arterial-progresion-enfermedad-renal-X1888970013001180

5. Anwar N, Riad M. A stochastic model for progression of chronic kidney disease. Journal of Engineering Research and Applications [Internet]. 2014 [citado 20 Nov 2017];4(11):8-19. Disponible en: https://www.ingentaconnect.com/content/doaj/22489622/2014/00000004/00000011/art00009?crawler=true

6. Chase HS, Hirsch SH, Mohan S, Rao MK, Radhakrishnan J. Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case controlled study. BMC Nephrol [Internet]. 2014 [citado 16 Dic 2017];15:187. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25431293

7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med [Internet]. 1999 Mar [citado 16 Dic 2017];130(6):461-70. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10075613

8. Kukla A, Adulla M, Pascual J, Samaniego M, Nanovic L, BeckerBN, et al. CKD stage-to-stage progression in native and transplant kidney disease. Nephrol Dial Transplant [Internet]. 2008 [citado 16 Dic 2017];23(2):693–700. Disponible en: https://academic.oup.com/ndt/article/23/2/693/1851285

9. Vejakama P, Ingsathit A, McEvoy M, Attia J, Thakkinstian A. Progression of chronic kidney disease: an illness-death model approach. BMC Nephrol [Internet]. 2017 [citado 16 Dic 2017];18(1):205. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493086/

10. Vejakama P, Ingsathit A, Attia J, Thakkinstian A. Epidemiological study of chronic kidney disease progression: a large-scale population-based cohort study. Medicine (Baltimore) [Internet]. 2015 [citado 16 Dic 2017];94(4):e475. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25634196

11. Boucquemont J, Heinze G, Jager KJ, Oberbauer R, Leffondre K. Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art. BMC Nephrol [Internet]. 2014 Mar [citado 16 Dic 2017];15(1):45. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24628838

12. Yang W, Xie D, Anderson AH, Joffe MM, Greene T, Teal V, et al. Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis [Internet]. 2014 [citado 16 Dic 2017];63(2):236-43. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24182662

13. Wyatt C. Kidney disease and HIV infection. Top Antivir Med [Internet]. 2017 Feb-Mar [citado 16 Dic 2017];25(1):13-6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5677039/

14. Arora P, Jalal K, Gupta A, Carter RL, Lohr JW. Progression of kidney disease in elderly stage 3 and 4 chronic kidney disease patients. Int Urol Nephrol [Internet]. 2017 [citado 16 Dic 2017];49(6):1033-40. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/28236138

15. Rizzetto F, Leal VO, Bastos LS, Fouque D, Mafra D. Chronic kidney disease progression: a retrospective analysis of 3-year adherence to a low protein diet. Ren Fail [Internet]. 2017 [citado 16 Dic 2017];39(1):357-62. Disponible en: https://www.ncbi.nlm.nih.gov/labs/articles/28152653/

16. Kovesdy CP, Coresh J, Ballew SH, Woodward M, Levin A, Naimark DM, et al. Past decline versus current eGFR and subsequent ESRD risk. J Am Soc Nephrol [Internet]. 2016 Aug [citado 16 Dic 2017];27(8):2447-55. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/26657867

17. Piccoli GB, Deagostini MC, Vigotti FN, Ferraresi M, Moro I, Consiglio V, et al. Which low-protein diet for which CKD patient? An observational personalized approach. Nutrition [Internet]. 2014 Aug [citado 21 Dic 2017];30(9):992-9. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25102817

18. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA [Internet]. 2014 [citado 21 Dic 2017];311(5):507-20. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24352797

19. McMullan CJ, Lambers-Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D, et al. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis [Internet]. 2014 Nov [citado 21 Dic 2017];64(5):714–22. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25064674

20. Rahman M, Yang W, Akkina S, Alper A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol [Internet]. 2014 Jul [citado 21 Dic 2017];9(7):1190-8. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/24832097

21. Hirayama A, Konta T, Kamei K, Suzuki K, Ichikawa K, Fujimoto S, et al. Blood pressure, proteinuria, and renal function decline: Associations in a large community-based population. Am J Hypertens [Internet]. 2015 [citado 21 Dic 2017];28(9):1150-6. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/25673040

22. Ahmed SS, Laila TR, Begum HA, Moniruzzaman M. Proteinuria in chronic kidney disease and its management. Medicine Today [Internet]. 2013 [citado 21 Dic 2017];25(1):36-41. Disponible en: https://www.banglajol.info/index.php/MEDTODAY/article/view/16070/11416

23. Turin TC, James M, Ravani P, Tonelli M, Manns BJ, Quinn R, Jun M, Klarenbach S, Hemmelgarn BR. Proteinuria and rate of change in kidney function in a community-based population. J Am Soc Nephrol [Internet]. 2013 Oct [citado 21 Dic 2017];24(10):1661-7. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/23833255

24. D´Achiardi Rey R, Vargas JG, Echeverri JE, Moreno M, Quiroz G. Factores de riesgo de enfermedad renal crónica. Rev Med [Internet]. 2011 [citado 21 Dic 2017];19(2):226-31. Disponible en: http://www.scielo.org.co/pdf/med/v19n2/v19n2a09.pdf

Downloads

Published

2018-07-02

How to Cite

1.
Cruz Abascal RE, Pino Pichs RL. Progression risk approach of chronic kidney disease. Experience in Botswana. Acta Méd Centro [Internet]. 2018 Jul. 2 [cited 2025 Jul. 1];12(3):293-301. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/970

Issue

Vol. 12 No. 3 (2018): July-September

Section

Original Articles

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).